<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401528</url>
  </required_header>
  <id_info>
    <org_study_id>AVB500-HV-001</org_study_id>
    <nct_id>NCT03401528</nct_id>
  </id_info>
  <brief_title>A Phase 1 AVB-S6-500 Safety and Tolerability Study</brief_title>
  <official_title>A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aravive, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aravive, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized single-blind, placebo-controlled, Phase 1, single ascending dose (SAD)&#xD;
      and repeat dose (RD), safety and tolerability study of AVB-S6-500 in healthy subjects. A SAD&#xD;
      portion of the study consists of 4 sequential dose escalation cohorts, whereas RD portion of&#xD;
      the study consists of a single cohort receiving 4 weekly doses of AVB-S6-500. In both SAD and&#xD;
      RD study arms, subjects are randomized to receive either a study intervention (AVB-S6-500) or&#xD;
      matching placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This study has two portions: a single ascending dose (SAD) portion consisting of 4 sequential dose escalation cohorts, and a repeat dose (RD) portion. In both study portions, subjects are randomized to receive either a study intervention (AVB-S6-500) or a placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of AVB-S6-500 - Adverse events</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Monitoring of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AVB-S6-500 - ECG</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Monitoring of 12 lead ECGs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AVB-S6-500 -physical examination</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Physical examination of body systems</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AVB-S6-500 - vital sign</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Vital sign measurment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of AVB-S6-500 - clinical laboratory assessments</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Routine lab hematology, serum chemistry and coagulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Serum concentration observed at end of a single dose and observed pre-dose during repeat doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Time to reach maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Terminal phase elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>The total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameter</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Concentration of the drug target</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose - AVB-S6-500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat Dose - AVB-S6-500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat Dose - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVB-S6-500</intervention_name>
    <description>AVB-S6-500 is an investigational drug.</description>
    <arm_group_label>Repeat Dose - AVB-S6-500</arm_group_label>
    <arm_group_label>Single Ascending Dose - AVB-S6-500</arm_group_label>
    <other_name>AVB500</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Repeat Dose - placebo</arm_group_label>
    <arm_group_label>Single Ascending Dose - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female&#xD;
&#xD;
          -  Age 18 - 55&#xD;
&#xD;
          -  Body mass index (BMI) ranging between 18 and 30 kg/m2, inclusive&#xD;
&#xD;
          -  Negative urine drug screen/alcohol breathalyzer results at Screening and at Day -1&#xD;
&#xD;
          -  Has not used tobacco products during the 3 months prior to Screening and agrees to&#xD;
             refrain from use throughout the study duration&#xD;
&#xD;
          -  Female subjects of child-bearing potential must agree to use one of the study-approved&#xD;
             effective contraceptive methods for the duration of the study and through 1 month&#xD;
             after completion of the final study visit&#xD;
&#xD;
          -  Male subjects must be either surgically sterilized or agree to use study-approved&#xD;
             effective contraceptive methods for the duration of the study and through 1 month&#xD;
             after completion of the final study visit&#xD;
&#xD;
          -  If female, a negative serum pregnancy test at Screening and urinary pregnancy test at&#xD;
             Day -1 is required&#xD;
&#xD;
          -  Able to read, understand, and provide signed informed consent&#xD;
&#xD;
          -  Able to communicate adequately with the investigator and to comply with the&#xD;
             requirements for the entire study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood pressure ≥ 140/90 mmHg or pulse &gt; 100 beats/minute at Screening&#xD;
&#xD;
          -  QTc intervals corrected for heart rate via the Fridericia method (QTcF) &gt; 450 msec&#xD;
             (males) and &gt; 480 msec (females) at Screening&#xD;
&#xD;
          -  Pregnant or a nursing female&#xD;
&#xD;
          -  Male with a pregnant partner&#xD;
&#xD;
          -  Currently enrolled in another clinical trial or has received treatment with an&#xD;
             investigational drug during the 30 days (or 5 half-lives, whichever is longer) prior&#xD;
             to dosing&#xD;
&#xD;
          -  History of substance or alcohol abuse or dependency within the past&#xD;
&#xD;
          -  Used any medications or over the-counter products within 14 days or 5 half lives&#xD;
             (whichever is longer) prior to administration of study medication, including&#xD;
             analgesics, hormonal contraceptives (oral contraceptive pills or implant), natural&#xD;
             food supplements, or dietary or herbal supplements including vitamins)&#xD;
&#xD;
          -  Donated blood in excess of 500 mL within 56 days prior to the dosing or intention of&#xD;
             donating during the study through the month after completing the study&#xD;
&#xD;
          -  Positive test results for hepatitis B virus (HBV) surface antigen, hepatitis C virus&#xD;
             antibody (HCV), or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  History or presence of any condition that, in the opinion of the Investigator, could&#xD;
             interfere with the study conduct or observation&#xD;
&#xD;
          -  A medical history of or any current clinically significant disorder, including but not&#xD;
             limited to: asthma, angioedema, bronchospasm, ulcer disease, gastrointestinal&#xD;
             bleeding, coagulation defects, hypertension, edema, heart failure, hypokalemia,&#xD;
             cardiovascular disease, hypersensitivity reaction to any biologic drug, significant&#xD;
             dermatologic diseases or condition that would significantly influence the immune&#xD;
             response&#xD;
&#xD;
          -  A serious illness, medical surgical procedure, or trauma resulting in missed work or&#xD;
             hospitalization within the 30 days preceding the beginning of study treatment&#xD;
&#xD;
          -  Received treatment for any type of cancer within the 5 years prior to enrollment&#xD;
&#xD;
          -  An employee, family member, or student of the Investigator or clinical site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas C Marbury, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orlando Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

